Rare Disease

Center for Rare Diseases continues to engage with rare disease patient communities during COVID-19 crisis

PRA Health Sciences’ Center for Rare Diseases is committed to engaging rare disease patient communities, and providing transparency, throughout the…

Creating Solutions to Ensure Endpoint Protection in Challenging Rare Disease Trial

The collection of high-quality endpoint data was paramount to the success of this Phase II program. Because this was the first clinical trial ever…

PRA Talks COVID-19 Impact on Rare Disease Clinical Trials with Patient Advocates

PRA’s Center for Rare Diseases understands that clinical trials are both a source of hope and care for people affected by a rare disease. The impact…

COVID-19 Impact on Rare Disease Clinical Trials

Rare disease patient organizations are coping with a broad range of other organizational challenges, including reduced funding, canceled fundraising…

Rare Diseases Newsletter Volume 16, April 2020

Guiding Principles for Interactions with Rare Disease Patient Advocacy Organizations

PRA acknowledges and thanks the members of the Rare Disease Advisory Committee (RDAC) who provided their valuable contributions to the development of…

A Critical Success Factor in Rare Disease Clinical Research: Patient Advocacy Collaboration

In most public sectors, understanding the end user’s perspective and building out a product strategy around it is nothing short of dogma. However, in…

PRA Hosts Rare Disease Day Event

World Rare Disease Day (WRDD) is an important time to raise awareness for the 7,000+ known rare diseases and the millions of people whose daily lives…

RARE DISEASES NEWSLETTER Volume 15, December 2019

Research Expertise